Marketing-authorisation holder · United States
Viiv Hlthcare
26 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
26 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 26
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| APRETUDE600mg/3ml (200mg/ml) · Suspension, extended release | Cabotegravir | United States | Marketed | 2021 |
| CABENUVA KIT400mg/2ml (200mg/ml); 600mg/2ml (300mg/ml) | 600mg/3ml (200mg/ml); 900mg/3ml (300mg/ml) · Suspension, extended release | Cabotegravir, Rilpivirine | United States | Marketed | 2021 |
| COMBIVIR150MG; 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Lamivudine, Zidovudine | United States | Not marketed | 1997 |
| DOVATO50mg base; 300mg · Tablet | Dolutegravir, Lamivudine | United States | Marketed | 2019 |
| EPIVIR10mg/ml · Solution | Lamivudine | United States | Marketed | 1995 |
| EPIVIR150mg | 300mg · Tablet | Lamivudine | United States | Marketed | 2004 |
| EPZICOM600MG BASE; 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Abacavir, Lamivudine | United States | Not marketed | 2004 |
| JULUCA50mg base; 25mg base · Tablet | Dolutegravir, Rilpivirine | United States | Marketed | 2017 |
| LEXIVA50mg base/ml · Suspension | Fosamprenavir | United States | Not marketed | 2007 |
| LEXIVA700MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Fosamprenavir | United States | Not marketed | 2003 |
| RESCRIPTOR100mg | 200mg · Tablet | Delavirdine | United States | Not marketed | 1997 |
| RETROVIR200MG | 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Zidovudine | United States | Not marketed | 1995 |
| RETROVIR10mg/ml · Injectable | Zidovudine | United States | Marketed | 1990 |
| RETROVIR50mg/5ml · Solution | Zidovudine | United States | Marketed | 1989 |
| RETROVIR100mg · Capsule | Zidovudine | United States | Marketed | 1987 |
| RUKOBIA600mg base · Tablet, extended release | Fostemsavir | United States | Marketed | 2020 |
| SELZENTRY20mg/ml · Solution | Maraviroc | United States | Marketed | 2016 |
| SELZENTRY150MG | 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 300MG | 75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Maraviroc | United States | Marketed | 2007 |
| TIVICAY10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 50MG BASE · Tablet | Dolutegravir | United States | Marketed | 2013 |
| TIVICAY PD5mg base · Tablet, for suspension | Dolutegravir | United States | Marketed | 2020 |
| TRIUMEQ600mg base; 50mg base; 300mg · Tablet | Abacavir, Dolutegravir, Lamivudine | United States | Marketed | 2014 |
| TRIUMEQ PD60mg base; 5mg base; 30mg · Tablet, for suspension | Abacavir, Dolutegravir, Lamivudine | United States | Marketed | 2022 |
| TRIZIVIR300MG BASE; 150MG; 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Abacavir, Lamivudine, Zidovudine | United States | Not marketed | 2000 |
| VOCABRIA30mg base · Tablet | Cabotegravir | United States | Marketed | 2021 |
| ZIAGEN20mg base/ml · Solution | Abacavir | United States | Marketed | 1998 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 26 | 26 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.